LTR Pharma Valuation

Is LTP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LTP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LTP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LTP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LTP?

Key metric: As LTP barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for LTP. This is calculated by dividing LTP's market cap by their current book value.
What is LTP's PB Ratio?
PB Ratio	64.1x
Book	AU$2.94m
Market Cap	AU$188.41m

LTP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3781.6x
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does LTP's PB Ratio compare to its peers?

The above table shows the PB ratio for LTP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	8.8x
AGN Argenica Therapeutics	6.6x	n/a	AU$92.9m
ALA Arovella Therapeutics	17.9x	n/a	AU$190.0m
PER Percheron Therapeutics	8.4x	19.8%	AU$78.4m
VLS Vita Life Sciences	2.4x	n/a	AU$116.0m
LTP LTR Pharma	64.1x	n/a	AU$188.4m

Price-To-Book vs Peers: LTP is expensive based on its Price-To-Book Ratio (64.1x) compared to the peer average (8.6x).

Price to Book Ratio vs Industry

How does LTP's PB Ratio compare vs other companies in the AU Pharmaceuticals Industry?

3 Companies	Price / Book	Estimated Growth	Market Cap
LGP Little Green Pharma	0.5x	110.1%	US$25.57m
EOF Ecofibre	0.4x	n/a	US$10.01m
CGB Cann Global	0.5x	n/a	US$3.69m

No more companies available in this PB range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: LTP is expensive based on its Price-To-Book Ratio (64.1x) compared to the Australian Pharmaceuticals industry average (4.1x).

Price to Book Ratio vs Fair Ratio

What is LTP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LTP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	64.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LTP's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.13

6.1%

AVITA Medical

US$342.3m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.98

0.5%

19.9%

Neuren Pharmaceuticals

AU$1.6b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU

AU$12.36

-26.0%

-17.0%